Should patient setup in lung cancer be based on the primary tumor? An analysis of tumor coverage and normal tissue dose using repeated positron emission tomography/computed tomography imaging.

PURPOSE Evaluation of the dose distribution for lung cancer patients using a patient setup procedure based on the bony anatomy or the primary tumor. METHODS AND MATERIALS For 39 patients with non-small-cell lung cancer, the planning fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) scan was registered to a repeated FDG-PET/CT scan made in the second week of treatment. Two patient setup methods were analyzed based on the bony anatomy or the primary tumor. The original treatment plan was copied to the repeated scan, and target and normal tissue structures were delineated. Dose distributions were analyzed using dose-volume histograms for the primary tumor, lymph nodes, lungs, and spinal cord. RESULTS One patient showed decreased dose coverage of the primary tumor caused by progressive disease and required replanning to achieve adequate coverage. For the other patients, the minimum dose to the primary tumor did not significantly deviate from the planned dose: -0.2 ± 1.7% (p = 0.71) and -0.1 ± 1.7% (p = 0.85) for the bony anatomy setup and the primary tumor setup, respectively. For patients (n = 31) with nodal involvement, 10% showed a decrease in minimum dose larger than 5% for the bony anatomy setup and 13% for the primary tumor setup. The mean lung dose exceeded the maximum allowed 20 Gy in 21% of the patients for the bony anatomy setup and in 13% for the primary tumor setup, whereas for the spinal cord this occurred in 10% and 13% of the patients, respectively. CONCLUSIONS In 10% and 13% of patients with nodal involvement, setup based on bony anatomy or primary tumor, respectively, led to important dose deviations in nodal target volumes. Overdosage of critical structures occurred in 10-20% of the patients. In cases of progressive disease, repeated imaging revealed underdosage of the primary tumor. Development of practical ways for setup procedures based on repeated high-quality imaging of all tumor sites during radiotherapy should therefore be an important research focus.

[1]  Philippe Lambin,et al.  Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. , 2005, International journal of radiation oncology, biology, physics.

[2]  P. Lambin,et al.  Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. , 2010, International journal of radiation oncology, biology, physics.

[3]  P. Lambin,et al.  Volume or position changes of primary lung tumor during (chemo-)radiotherapy cannot be used as a surrogate for mediastinal lymph node changes: the case for optimal mediastinal lymph node imaging during radiotherapy. , 2011, International journal of radiation oncology, biology, physics.

[4]  J C Stroom,et al.  Inclusion of geometrical uncertainties in radiotherapy treatment planning by means of coverage probability. , 1999, International journal of radiation oncology, biology, physics.

[5]  Jan J W Lagendijk,et al.  MRI/linac integration. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  John Wong,et al.  Quantification of tumor volume changes during radiotherapy for non-small-cell lung cancer. , 2009, International journal of radiation oncology, biology, physics.

[7]  P. Lambin,et al.  Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. , 2008, International journal of radiation oncology, biology, physics.

[8]  Agung Hertanto,et al.  Observation of interfractional variations in lung tumor position using respiratory gated and ungated megavoltage cone-beam computed tomography. , 2007, International journal of radiation oncology, biology, physics.

[9]  Philippe Lambin,et al.  PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. , 2007, International journal of radiation oncology, biology, physics.

[10]  M. V. van Herk,et al.  The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy. , 2000, International journal of radiation oncology, biology, physics.

[11]  Patrick A Kupelian,et al.  Serial megavoltage CT imaging during external beam radiotherapy for non-small-cell lung cancer: observations on tumor regression during treatment. , 2005, International journal of radiation oncology, biology, physics.

[12]  Philippe Lambin,et al.  Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical study. , 2006, International journal of radiation oncology, biology, physics.

[13]  Wolfgang A Tomé,et al.  Tumor volume changes on serial imaging with megavoltage CT for non-small-cell lung cancer during intensity-modulated radiotherapy: how reliable, consistent, and meaningful is the effect? , 2006, International journal of radiation oncology, biology, physics.

[14]  Marcel van Herk,et al.  Different styles of image-guided radiotherapy. , 2007 .

[15]  Marcel van Herk,et al.  Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis. , 2006, International Journal of Radiation Oncology, Biology, Physics.

[16]  Jan-Jakob Sonke,et al.  Variability of four-dimensional computed tomography patient models. , 2008, International journal of radiation oncology, biology, physics.

[17]  Philippe Lambin,et al.  Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Suresh Senan,et al.  Motion analysis of 100 mediastinal lymph nodes: potential pitfalls in treatment planning and adaptive strategies. , 2008, International journal of radiation oncology, biology, physics.

[19]  Suresh Senan,et al.  Time trends in target volumes for stage I non-small-cell lung cancer after stereotactic radiotherapy. , 2006, International journal of radiation oncology, biology, physics.

[20]  P. Lambin,et al.  Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial. , 2008, International journal of radiation oncology, biology, physics.

[21]  P. Lambin,et al.  Time trends in nodal volumes and motion during radiotherapy for patients with stage III non-small-cell lung cancer. , 2007, International journal of radiation oncology, biology, physics.

[22]  Jan-Jakob Sonke,et al.  Adaptive radiotherapy for lung cancer. , 2010, Seminars in radiation oncology.

[23]  J. Lebesque,et al.  Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. , 2006, International journal of radiation oncology, biology, physics.